Cholangiocarcinoma Pipeline Analysis Report 2026

Cholangiocarcinoma is a rare but aggressive cancer arising from the bile duct epithelium. According to Aaron Schindler et al., 2025, it accounts for nearly 10-15% of primary liver cancers. Treatment includes surgery, chemotherapy, radiation, and emerging targeted and immunotherapies. According to the Cholangiocarcinoma Pipeline Analysis, increasing molecular research, biomarker-driven therapies, and rising incidence linked to chronic liver diseases are driving pipeline growth, with significant advancements expected in precision oncology and novel drug development.

Report Coverage

The Cholangiocarcinoma Pipeline Analysis Report gives comprehensive insights into cholangiocarcinoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for cholangiocarcinoma. The cholangiocarcinoma report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The Cholangiocarcinoma Pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with cholangiocarcinoma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to cholangiocarcinoma.

Cholangiocarcinoma Pipeline Outlook

Cholangiocarcinoma is a rare, aggressive malignancy arising from the epithelial cells of the bile ducts. It occurs due to chronic inflammation, genetic mutations, and conditions such as primary sclerosing cholangitis, liver fluke infections, and biliary abnormalities, leading to uncontrolled cellular proliferation and tumor formation within intrahepatic or extrahepatic bile ducts.

Cholangiocarcinoma treatment involves surgical resection, chemotherapy regimens such as gemcitabine and cisplatin, targeted therapies against specific mutations, immunotherapy, and palliative interventions, including biliary drainage to manage advanced or unresectable disease. In March 2024, Incyte Corporation advanced pemigatinib, a fibroblast growth factor receptor inhibitor, in its cholangiocarcinoma pipeline, demonstrating improved progression-free survival in patients with fibroblast growth factor receptor 2 fusions, highlighting its potential as a targeted therapy option in advanced-stage disease management.

Cholangiocarcinoma Epidemiology

According to the American Cancer Society, bile duct cancer (cholangiocarcinoma) remains rare, with approximately 8,000 new cases diagnosed annually in the United States, although underdiagnosis and misclassification may lead to underestimation of the true incidence. As per Masashi Mizumoto et al., 2023, intrahepatic cholangiocarcinoma shows higher prevalence in Asia, with age-adjusted rates of 1.25 per 100,000 person-years in men and 0.77 in women in Japan. According to Deepak Kumar Bhojwani et al., 2025, the highest burden in Central India is observed in the 51-60-year age group (29.17%), followed by 41-50 years (23.8%), indicating a middle-aged predominance.

Cholangiocarcinoma - Pipeline Therapeutic Assessment

This section of the report covers the analysis of cholangiocarcinoma drug candidates based on several segmentations including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The cholangiocarcinoma pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecule
• Peptide
• Polymer
• Monoclonal Antibody
• Gene Therapy

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Cholangiocarcinoma Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total cholangiocarcinoma clinical trials, with 62%, indicating strong mid-stage clinical activity and promising therapeutic advancement. Phase I at 25% supports early validation of novel candidates. Phase III with 10% enhances near-term commercialization prospects.

Cholangiocarcinoma Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the cholangiocarcinoma pipeline analysis include small molecules, monoclonal antibodies, gene therapies, polymers, and peptides. The cholangiocarcinoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for cholangiocarcinoma. Targeted and immune-based drug therapies are emerging in the cholangiocarcinoma treatment pipeline, driven by advances in molecular profiling and precision oncology. For instance, zenocutuzumab, a bispecific antibody targeting the HER2-HER3 receptor axis in NRG1 fusion-positive cholangiocarcinoma, has shown meaningful clinical responses in early-phase trials. Moreover, several agents across kinase inhibitor and monoclonal antibody classes are under evaluation to improve survival outcomes and address limited existing treatment options.

Cholangiocarcinoma Clinical Trials - Key Players

The report for the cholangiocarcinoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed cholangiocarcinoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in cholangiocarcinoma clinical trials:

• Eli Lilly and Company
• Incyte Corporation
• Seagen
• Elevar Therapeutics
• Compass Therapeutics
• TCR2 Therapeutics
• Elicio Therapeutics
• Eisai Co., Ltd.
• Servier
• TriSalus Life Sciences, Inc.

Cholangiocarcinoma - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for cholangiocarcinoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of cholangiocarcinoma drug candidates.

Drug: TT-00420 (Tinengotinib)

Tinengotinib (TT-00420) is a spectrum-selective, oral small-molecule multi-kinase inhibitor that is being developed by TransThera Sciences (Nanjing), Inc. It is targeting FGFR2 fusion/rearranged or mutated signaling pathways in advanced intrahepatic cholangiocarcinoma by inhibiting Aurora A/B, VEGFR, FGFR1/2/3, JAK1/2, and CSF1R, thereby suppressing tumor proliferation, angiogenesis, and immune evasion. In a Phase III, open-label, randomized study, it is being evaluated versus chemotherapy in patients with unresectable or metastatic disease after first-line therapy. The study is enrolling approximately 138 patients and is expected to be completed by December 2030.

Drug: GNS561 + Trametinib

GNS561 is a first-in-class investigational lysosomotropic agent being developed by Genfit and is being administered orally in combination with the oral MEK inhibitor trametinib in a Phase 1b/2a open-label, multicenter study for advanced KRAS-mutated cholangiocarcinoma. The study is examining safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor efficacy in patients after failure of standard first-line therapy. The drug targets lysosomal dysfunction and autophagy pathways, while trametinib inhibits MAPK signaling to suppress tumor growth and survival. The study is estimated to be completed in October 2026 while continuing dose optimization and patient evaluation.

Biological: SynKIR-110

SynKIR-110 is being sponsored by Verismo Therapeutics and is currently undergoing a Phase 1, first-in-human study to evaluate its safety, feasibility, and preliminary anti-tumor activity in patients with mesothelin-expressing cholangiocarcinoma, ovarian cancer, and mesothelioma. It is an autologous CAR T-cell therapy engineered with a KIR-based split-signaling platform, administered as a single intravenous infusion following lymphodepleting chemotherapy. The study is assessing dose escalation using a 3+3 design to determine the maximum tolerated or feasible dose. It is expected to be completed by December 2027, while the trial is examining tumor regression and safety over a 12-month follow-up period.

Key Questions Answered in the Cholangiocarcinoma Pipeline Insight Report

• Which companies/institutions are leading cholangiocarcinoma drug development?
• Which company is leading the cholangiocarcinoma pipeline development activities?
• What is the current cholangiocarcinoma commercial assessment?
• What are the opportunities and challenges present in the cholangiocarcinoma pipeline landscape?
• What is the efficacy and safety profile of cholangiocarcinoma pipeline drugs?
• Which company is conducting major trials for cholangiocarcinoma drugs?
• Which companies/institutions are involved in cholangiocarcinoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in cholangiocarcinoma?

Reasons To Buy This Report

The Cholangiocarcinoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for cholangiocarcinoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into cholangiocarcinoma collaborations, regulatory environments, and potential growth opportunities.